Partner in Progress: Photocure

BCAN proudly partners with Photocure, united in our shared purpose to improve the lives of bladder cancer patients today and ensure better tomorrows for them and their loved ones.

The following content is sponsored by Photocure.

Photocure’s unique technology, which makes cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway, and is listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit www.photocure.com.

Learn more about bladder cancer, and detecting it, from people who have gone through it themselves by watching these short videos.

You can read more on Photocure’s web site about support services for bladder cancer patients.

What is Cysview®?

Photocure’s FDA-approved Cysview® makes non-muscle invasive bladder cancer (NMIBC) tumors glow bright pink under blue light during Blue Light Cystoscopy (BLC®).

Cysview solution is placed into the cancer patient’s bladder via a catheter one hour prior to BLC. During BLC, Cysview then enhances tumor visibility so urologists can remove cancer more completely than with standard White Light Cystoscopy (WLC) alone.

Indication: Cysview is an optical imaging agent indicated for use in the cystoscopic detection of carcinoma of the bladder, including carcinoma in situ (CIS), among patients suspected or known to have lesion(s) on the basis of a prior cystoscopy, or in patients undergoing surveillance cystoscopy for carcinoma of the bladder. Cysview is used with the KARL STORZ D-Light C Photodynamic Diagnostic (PDD) system to perform BLC as an adjunct to WLC.

Cysview® and BLC® are registered trademarks of Photocure ASA.

What is Blue Light Cystoscopy (BLC®)?

When blue light technology and Cysview are available, they are used together with white light in the BLC procedure. The urologist first views the bladder with white light, then switches to blue light to see any bright pink tumor tissue areas that Cysview has caused to fluoresce. The urologist then switches between white and blue light to perform the necessary tumor removal.

Read more about Cysview and Blue Light Cystoscopy.

Video

Below is a video from Photocure about what a bladder cancer patient’s journey might hold, from diagnosis to treatment.

Podcast

In this special Bladder Cancer Matters podcast, host Rick Bangs features BCAN’s February 2025 Partner in Progress,  Photocure. Anders Neijber, Photocure’s Chief Medical Officer, dives into the company’s pioneering work in bladder cancer diagnosis and surveillance, including the groundbreaking use of Blue Light Cystoscopy.

Important Risk & Safety Information for Cysview® (hexaminolevulinate HCl)

Cysview is an optical imaging agent used to detect non-muscle invasive bladder cancer in patients suspected or known to have lesion(s) on the basis of a prior cystoscopy, or in patients undergoing surveillance cystoscopy for bladder cancer. Cysview is not a replacement for random bladder biopsies or other procedures used in the detection of bladder cancer. False-positive fluorescence may occur due to inflammation, trauma from past cystoscopies, scar tissue, previous bladder biopsy, and recent Bacillus Calmette-Guérin (BCG) therapy or intravesical chemotherapy.

Anaphylactoid shock, hypersensitivity reactions, bladder pain, bladder inflammation (cystitis), and abnormal urine tests have been reported after administration of Cysview. The most common adverse reactions seen in clinical trials were bladder spasm, trouble urinating, discomfort when urinating, frequent urination, blood in the urine, and bladder pain.

Cysview should not be used in patients with large amounts of blood in their urine, any known allergy to Cysview or any derivative of aminolevulinic acid, or porphyria, a condition that means you already have high levels of porphyrins in your body. No specific drug interaction studies have been performed.

There are no available data on Cysview use in pediatric patients, pregnant women, or nursing mothers.

Please see Full Prescribing Information here.

This information is intended for U.S audiences only.